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The type 1 Simpson–Golabi–Behmel overgrowth syndrome (SGBS1) is caused by loss-of-function mutations of the X-linked
GPC3 gene encoding glypican-3, a cell-surface heparan sulfate proteoglycan that apparently plays a negative role in growth
control by an unknown mechanism. Mice carrying a Gpc3 gene knockout exhibited several phenotypic features that
resemble clinical hallmarks of SGBS1, including somatic overgrowth, renal dysplasia, accessory spleens, polydactyly, and
placentomegaly. In Gpc3/H19 double mutants (lacking GPC3 and also carrying a deletion around the H19 gene region that
causes bialellic expression of the closely linked Igf2 gene by imprint relaxation), the Gpc3-null phenotype was exacerbated,
while additional SGBS1 features (omphalocele and skeletal defects) were manifested. However, results from a detailed
comparative analysis of growth patterns in double mutants lacking GPC3 and also IGF2, IGF1, or the type 1 IGF receptor
(IGF1R) provided conclusive genetic evidence inconsistent with the hypothesis that GPC3 acts as a growth suppressor by
sequestering or downregulating an IGF ligand. Nevertheless, our data are compatible with a model positing that there is
downstream convergence of the independent signaling pathways in which either IGFs or (indirectly) GPC3
participate. © 2002 Elsevier Science (USA)
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Mammalian growth is regulated by the actions of gene
products participating in signaling pathways that predomi-
nantly promote or inhibit cell proliferation through sys-
temic or local effects (reviewed by Efstratiadis, 1998). De-
rangement of such genetic controls can lead to conditions of
growth retardation or overgrowth.
Human overgrowth syndromes comprise an ill-defined
group of disorders characterized by prenatal and postnatal
higher-than-normal weight and length usually associated
with various malformations (reviewed by Cohen, 1999). In a
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All rights reserved.minority of these conditions, however, a genetic cause has
been determined. This is the case for the Simpson–Golabi–
Behmel syndrome type 1 (SGBS1; MIM 312870; reviewed by
Neri et al., 1998; Lin et al., 1999; Li et al., 2001) caused by
mutations of the X-linked gene GPC3 (Pilia et al., 1996),
which resides on Xq26 and encodes glypican-3, one of six
known mammalian cell-surface heparan sulfate proteogly-
cans attached to the plasma membrane lipid via a glyco-
sylphosphatidylinositol (GPI) anchor (see Selleck, 1999,
2000, 2001; Bernfield et al., 1999; Perrimon and Bernfield,
2000, 2001; De Cat and David, 2001). Today, a total of120
SGBS1 patients have been described, and GPC3 deletions/
mutations have been identified in 40% (26/65) of the
examined cases (see Lin et al., 1999; Li et al., 2001). In
addition, a second SGBS locus associated with a more
severe form of the disorder (SGBS2; MIM 300209; see
Terespolsky et al., 1995) has been mapped in a single familyarg@cancercenter.columbia.edu.
0012-1606/02 $35.00185
(four maternally related male cousins) within an 6-Mb
region of Xp22 (Brzustowicz et al., 1999). In male patients,
in addition to excessive growth, the rather broad spectrum
of SGBS1 manifestations includes coarse facies, macroglos-
sia, organomegaly, renal dysplasia, cardiac defects, and
skeletal malformations.
The mechanistic relationship between the pathogenesis
of developmental abnormalities in SGBS1 and various
GPC3 loss-of-function mutations (large and small deletions
and also nonsense, frameshift, missense, and splice-site
mutations; Pilia et al., 1996; Hughes-Benzie et al., 1996;
Lindsay et al., 1997; Xuan et al., 1999; Veugelers et al.,
2000) continues to remain unknown. It is thought, how-
ever, that glypicans can function as coreceptors affecting
particular signaling pathways involved in proliferative and
morphogenetic processes by binding and modulating the
actions of growth factors and morphogens (Perrimon and
Bernfield, 2000). In this context, it can be surmised that the
manifestation of overgrowth in SGBS1 would result from
elimination of the normal GPC3 function that inhibits
growth and/or promotes apoptosis.
SGBS exhibits overlapping phenotypic features with the
Beckwith–Wiedemann syndrome (BWS; MIM 130650), a
genetically heterogeneous and complex overgrowth disor-
der characterized by macrosomia, macroglossia, abdominal
wall defects, and other manifestations (reviewed by Elliot
and Maher, 1994; Weng et al., 1995; Weksberg and Squire,
1996; Li et al., 1998; Cohen, 1999; Maher and Reik, 2000).
In a subset of BWS cases, excess of growth-promoting IGF2
during embryonic development appears to be causally in-
volved in pathogenesis (see Morison and Reeve, 1998; Li et
al., 1998; Maher and Reik, 2000). Despite the fact that BWS
and SGBS are distinct clinical entities of different etiology,
an involvement of IGF signaling in SGBS was considered as
possible because IGF2 overexpression in mouse mutants
caused overgrowth and other aspects of the BWS phenotype
(Eggenschwiler et al., 1997; Sun et al., 1997), but features
resembling hallmarks of SGBS1 were also manifested (Egg-
enschwiler et al., 1997).
An attractive model that was previously advanced pos-
ited that GPC3 potentially binds and somehow sequesters
or downregulates IGF2 (Hughes-Benzie et al., 1996; Pilia et
al., 1996). The validity of this hypothesis remained ques-
tionable, however, because preliminary biochemical data
suggesting a human GPC3–IGF2 interaction (Pilia et al.,
1996; Xu et al., 1998) were not reproduced with OCI-5 (the
rat GPC3 homolog; Song et al., 1997). On the other hand,
some GPC3–IGF2 relationship was implied by the observa-
tion that cell line-specific promotion of apoptosis by OCI-5
was rescued by adding IGF2 to the culture medium (Gonza-
lez et al., 1998). Still, the possibility remained that this
evidence might have simply reflected ordinary antiapop-
totic signaling through the type 1 IGF receptor (IGF1R; see
Baserga et al., 1997).
Genetic experiments with mouse mutants have estab-
lished that, among the classic growth factors, the signaling
system consisting of the IGFs (IGF1 and IGF2) and their
cognate receptor (IGF1R) is the major determinant of mam-
malian growth (see Efstratiadis, 1998; Lupu et al., 2001). In
rodents, IGF2 is essential for normal embryonic growth
(Igf2 expression ceases after weaning; DeChiara et al., 1990,
1991), whereas IGF1 has a continuous growth-promoting
function throughout development (Liu et al., 1993; Baker et
al., 1993). Because of reduced growth rate, Igf1 nullizygotes
exhibit 60% of normal weight at birth (60%N) and, if
they survive depending on genetic background, they be-
come 30%N in size at the age of 2 months. Because the
Igf2 gene is subject to parental imprinting and only the
paternal allele is expressed in most tissues (DeChiara et al.,
1991), the heterozygotes with a paternally derived mutated
allele (Igf2/p) and the Igf2 nullizygotes (Igf2/) are pheno-
typically indistinguishable; they are fully viable dwarfs
with 60%N birth weight (this relative size is maintained
throughout life). Igf1r nullizygotes are severely growth
retarded (45%N birth weight) and die invariably immedi-
ately after birth.
To investigate genetically whether there is a relationship
between GPC3 and IGF2 in growth control, we sought to
generate double-mutant mice carrying knockouts of both
the Gpc3 and Igf2 genes and compare their phenotype with
the phenotypes of the respective single mutants. For the
purpose of these matings, we generated mutants lacking
GPC3 and used available Igf2 mutant mice. While this
work was in progress, targeted inactivations of Gpc3 were
also described independently by two other groups (Cano-
Gauci et al., 1999; Paine-Saunders et al., 2000), but genetic
analyses in connection to the IGFs were not included in
these reports. Moreover, despite manifestation of over-
growth in all three cases, some phenotypic differences were
noted between our data and the published results (see
Results and Discussion).
In the genetic investigation of GPC3 function in relation
to IGF signaling, our prediction was that, if overgrowth in
the absence of GPC3 is due to excess of unleashed IGF
ligand (which under normal conditions in wild-type mice is
sequestered by GPC3), the phenotype of Gpc3/Igf2 double
mutants would be identical to that of single mutants
lacking only IGF2. This prediction was not fulfilled, as
progeny with a body size intermediate between that of Igf2
mutants and wild-type mice were obtained. Similar obser-
vations were made with additional double mutants that we
generated, lacking GPC3 and IGF1 or GPC3 and IGF1R, to
ascertain whether any IGF signaling at all was related to
GPC3 function. Thus, conclusive evidence was provided
demonstrating that the GPC3 function is IGF-independent.
This conclusion was further supported by using a reciprocal
experimental design and generating double mutants lacking
GPC3 and also overexpressing IGF2 because of a deletion
around the H19 gene (H19) that causes bialellic expression
of the imprinted, closely linked Igf2 gene. Again, results
inconsistent with a model positing a GPC3–IGF2 interac-
tion were obtained, as the absence of GPC3 in Gpc3//H19
double mutants did not augment the overgrowth of single
H19 mutants that results from excess of IGF2.
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MATERIALS AND METHODS
Gpc3 Gene Targeting and Breeding of Mutants
A targeting vector (Fig. 1a) was constructed in several steps from
subcloned fragments of a BAC clone carrying exon 1 and flanking
sequences of the murine Gpc3 gene that was isolated from a
129/SvJ genomic library and characterized by restriction analysis
and partial DNA sequencing. The final construct (cloned into
pBluescript II SK; Stratagene) consisted of a 2.25-kb HindIII–Bgl II
5 genomic fragment, a neomycin resistance gene (neo) cassette
under the control of the Pgk gene promoter (for positive selection
with G418; 1.6 kb), a 3.9-kb EagI–HindIII 3 genomic fragment, and
a -actin promoter-driven diphtheria toxin A gene cassette (for
negative selection against random integration; see Yagi et al.,
1990). Thus, a 1.0-kb BglII–EagI genomic fragment containing exon
1 flanked by 0.6 kb of 5 and 0.1 kb of 3 sequences was replaced
with the neo cassette.
Linearized targeting vector DNA was introduced by electropora-
tion into ES cells [W9.5; 129/Sv (JR2448) genetic background; see
Ge´rard et al., 1999] and, after drug selection, DNA of resistant
clones was analyzed by Southern blotting using a probe correspond-
ing to genomic sequence downstream from the 3 region of homol-
ogy in the vector (0.7-kb HindIII fragment; Fig. 1a). Of 69 G418-
resistant clones, 12 were targeted correctly (single insertion) and 2
of them were injected into C57BL/6J host blastocysts, to generate
chimeras transmitting the mutation (no phenotypic differences
were observed between mice generated from the independent ES
clones).
Male chimeras were mated with wild-type C57BL/6J or 129/
Sv/Ev females, and F1 heterozygous female progeny were crossed
with males carrying Igf1, Igf2, or Igf1r targeted mutations (for
details, see Results and Discussion). To initiate the generation of
progeny carrying the Gpc3 mutation in combination with a dele-
tion mutation of the H19 gene (H19; see Results and Discussion),
transmitting chimeras were first mated with H19/ females. The
strains of mutant mice (other than those lacking GPC3) that were
used in this study and procedures for their genotyping have been
described previously (see DeChiara et al., 1990; Liu et al., 1993;
Leighton et al., 1995). Histological and anatomical analyses of
embryos and tissues, including skeletal preparations, were per-
formed as described (Eggenschwiler et al., 1997).
DNA and RNA Analyses
For genotyping by Southern analysis, DNA was prepared from
yolk sacs of embryos or the tail tip of 10-day-old mice. Mice were
genotyped for the Gpc3 mutation by digesting the DNA with EcoRI
and hybridizing the blots with the 0.7-kb HndIII probe (Fig. 1a), as
described above for targeted ES cells.
For Northern analysis of total embryonic RNA, blots were
hybridized with a 763-bp Gpc3 cDNA probe (Pellegrini et al., 1998)
representing most of the sequence of exons 3–5 (positions 628-
1390; GenBank Accession No. AF185614). Nonisotopic in situ
hybridization analysis on frozen sections was performed as de-
scribed (Wilkinson, 1992), using digoxigenin-labeled sense and
antisense RNA probes corresponding to a region of Gpc3 cDNA
(positions 1020–1918).
Protein Analysis
Relative amounts of IGF2 in e18.5 embryonic extracts or serum
and in e16.5 amniotic fluid were determined by Western blotting
performed as described (Eggenschwiler et al., 1997). The primary
goat polyclonal antibody (Research Diagnostics) used at a concen-
tration of 1 g/ml was raised against amino acids 25–44 of the
human IGF2 precursor. The secondary antibody was biotinylated
sheep anti-goat IgG (Boehringer) used at a 1:2500 dilution. The
immunoreactive bands were visualized with ECL detection re-
agents (Amersham). Quantitation of luminescent signals was per-
formed on a Kodak Digital Science 1D 440CF Imaging Station. To
determine mutant/wild-type ratios, IGF2 arbitrary values were first
normalized, using as internal standards either -fetoprotein (serum)
or HMG-I(Y) (embryonic extracts) that was detected with rabbit
polyclonal antibodies (from ICN Biochemicals and D. Thanos,
respectively).
Biochemical Analyses
Blood glucose levels were determined by using a digital glucom-
eter. Disaccharidase activities in small intestine homogenates were
measured as described (Koldovsky et al., 1969), and specific activi-
ties were expressed in international units (moles substrate hydro-
lyzed per minute per g protein).
Growth Analysis
Cumulative postnatal growth curves are best fitted with a
logistic equation W  A/1  exp[b(t  c)], where W and A are the
weight at time t and the asymptotic weight, respectively, while b
and c are constants. Body weights were determined on fixed
postnatal days for all mice and averages were calculated for each
genotype. Considering that postnatal growth is triphasic, these
average weight data were fitted simultaneously using a computer
program (SigmaPlot) by summation of three logistic functions with
different sets of A, b, and c values (see Koops, 1986; Koops et al.,
1987). From each fit, curves of predicted absolute growth rates
(dW/dt) were derived by subtracting the value of cumulative weight
at each day (Wi) from that estimated for the previous day (Wi1).
Absolute growth rates were then transformed to specific growth
rates [i.e., growth rates per unit size; (dW/dt)  (1/W)] using weight
values for normalization: (Wi  Wi1)/[1/2(Wi  Wi1)]. Organ
weights were determined as described (Eggenschwiler et al., 1997).
RESULTS AND DISCUSSION
Targeted Disruption of the Mouse Gpc3 Gene
To generate mutants lacking GPC3 functions, we re-
placed, by targeting, the Gpc3 exon1 (carrying the ATG
initiation codon) and flanking sequences with a neo gene
cassette in ES cells (see Fig. 1a, and Materials and Methods)
and produced chimeras transmitting the mutation to their
progeny (Fig. 1b). The targeted allele was designated
Gpc3ex1, but it will be referred to here simply as Gpc3.
Northern analysis of total RNA isolated from genotyped
e12.5 embryos using a Gpc3 cDNA probe showed that Gpc3
mRNA was undetectable in mutants lacking GPC3 (Fig.
1c). Thus, targeting of the Gpc3 locus resulted in generation
of a null mutation, as expected from the deletion of at least
some portion of the presumptive promoter region together
with exon 1.
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Genetic Crosses
To test genetically whether there is a relationship be-
tween GPC3 function and IGF signaling, we performed
three types of crosses and generated double mutants lacking
GPC3 and IGF2 (“G/II cross”), GPC3 and IGF1 (“G/I
cross”), or GPC3 and IGF1R (“G/R cross”). In a fourth cross,
using H19 mutants (Leighton et al., 1995; Eggenschwiler
et al., 1997), we generated double mutants lacking GPC3
but overexpressing IGF2 (“G/H cross”). In mice, the pater-
nally expressed, imprinted Igf2 gene is closely linked to the
reciprocally imprinted H19 locus encoding a nontranslat-
able RNA of unknown function. In progeny with a mater-
nally inherited deletion mutation (H19), which eliminates
H19 and upstream sequence containing an insulator ele-
ment (see Leighton et al., 1995; Wolffe, 2000), the normally
silent maternal Igf2 allele present in cis becomes transcrip-
tionally active. As a consequence, Igf2 is expressed bialleli-
cally and this results in a twofold increase of IGF2 tissue
levels and overgrowth (birth weight 130%N).
To initiate all crosses, male chimeras transmitting the
Gpc3 mutation in 129/Sv genetic background were mated
with wild-type C57BL/6J females, to obtain heterozygous
Gpc3/ females (129/Sv C57BL/6J hybrids; 129B6). The
latter were crossed: (1) with Igf2/p males (G/II cross); (2)
with Igf1/ males, to generate and then intercross (G/I
cross) double heterozygous females (Gpc3//Igf1/) and
males hemizygous for the Gpc3 mutation and heterozygous
for the Igf1 mutation (Gpc3//Igf1/); and (3) with Igf1r/
males, to generate and then intercross (G/R cross) Gpc3//
Igf1r/ female and Gpc3//Igf1r/ male progeny. To com-
bine the Gpc3 and H19 mutations, male transmitting
chimeras were first mated with H19/ females, to gener-
ate Gpc3//H19/ females, which were then crossed
with Gpc3 males (G/H cross). The genotypes of progeny
derived from the described breeding schemes are shown in
Table 1. This Table also includes limited results of matings
in pure 129 background (crosses of chimeras with 129
females).
In the G/II cross, the129B6 Gpc3/ females were mated
with males carrying the Igf2 mutation in inbred 129 back-
ground. Thus, the progeny were enriched in 129 strain
component (up to 3/4). On the other hand, the progeny of
the G/R cross were derived from parents enriched in B6
component (up to 3/4), which were generated by matings of
the Gpc3/ 129B6 female hybrids with Igf1r/ male
partners from a purebred B6 colony. The background of the
progeny derived from the G/H cross was also mixed
129B6, but the relative contributions of the components
are unknown (records of the breeding history of the H19
colony were not kept). Finally, the animals used for the G/I
cross and their offspring carried components of four strain
backgrounds (129, B6, MF1, and DBA) in variable mixtures.
The particular background of Igf1/ heterozygotes (MF1/
DBA) was chosen empirically during previous experiments
(see Lupu et al., 2001), to increase the frequency of surviv-
ing nullizygotes in case of intercrossing, as there is a
strain-dependent, high incidence of neonatal lethality
among Igf1/ mice (Liu et al., 1993). Despite strain differ-
ences, pairwise comparisons of weight distributions be-
tween progeny of the same age and genotype from the four
crosses did not reveal any statistically significant differ-
ences (Student’s t test; P  0.05).
Phenotypic Features of Mutants
In addition to overgrowth (discussed in detail in a sepa-
rate section), which is readily evident in Gpc3/ and
Gpc3/ neonates compared with their normal siblings (Fig.
2a), the lack of GPC3 results in reduced survival and
manifestation of other abnormalities described below.
Viability. Three Gpc3 knockouts were generated inde-
pendently by using ES cells from 129 substrains known to
have differences in genetic backgrounds (see Simpson et al.,
1997; Threadgill et al., 1997): 129/J (Cano-Gauci et al.,
1999), 129/SvJ (Gpc3tm108Sau allele in RW4 ES cells; Paine-
Saunders et al., 2000), and 129/Sv (JR2448; this work). An
insertional mutation derived separately from a gene trap
protocol was in 129/Ola background (Gpc3TgN(geo)ex136Ska al-
lele in CGR8 ES cells; Paine-Saunders et al., 2000). In all
cases, transmitting chimeras were mated with B6 females
(generation of F1 progeny). Phenotypic differences between
the t108 and Ex136 mutations were not observed and there
was no incidence of embryonic lethality in any of the
mutations. Postnatally, however, variable, strain-dependent
lethality was observed in all cases.
Table 1 shows the numbers of recovered stillborn progeny
from the four crosses that we described above (G/II, G/I,
G/R, and G/H) and also the numbers of additional mice that
died before weaning (after weaning, some animals were
sacrificed for analysis, but other deaths were not observed).
These results were used to assess the viability of single
mutants lacking GPC3 and double Gpc3//H19m/ or
Gpc3//H19m/ mutants. Because mice lacking IGF1R
die invariably immediately after birth, while neonates lack-
ing IGF1 exhibit variable, strain-dependent lethality, the
data concerning double mutants nullizygous for either one
of these mutations and also lacking GPC3 were not taken
into consideration.
Maximum-likelihood statistical analysis of the data first
indicated that there are no significant differences between
the four sets of data in regard to the viability of Gpc3/ or
Gpc3/ mutants and wild-type controls. Thus, in evaluat-
ing death frequencies, all data were considered collectively.
As Table 1 shows, random deaths of newborn progeny were
recorded not only for male or female mutants lacking
GPC3, but also for wild-type animals and Gpc3/ heterozy-
gous females. Our analysis showed that the frequency of
stillborn Gpc3 and Gpc3/ mutants was not significantly
different from that of other random deaths. In contrast,
excluding stillborn animals, the frequency of mutants lack-
ing GPC3 that died before weaning (8/76; 10.5%) was
statistically significantly higher than that expected for
random events (P  0.025 or P  0.034, depending on
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whether only wild-type or both wild-type and Gpc3/
heterozygous mice are taken into consideration). Neverthe-
less, the Gpc3/ or Gpc3/ hybrids with variably segregat-
ing strain components were able to survive in their vast
majority (90%), and this gave us the opportunity to
analyze postnatal growth in detail (see below), a study not
performed previously with other Gpc3 mutants (Cano-
Gauci et al., 1999; Paine-Saunders et al., 2000).
In contrast to surviving hybrids, matings in pure 129
background, albeit limited, indicated that, in the absence of
GPC3, modifiers in this genetic background affect signifi-
cantly postnatal viability, since we were able to recover
only three mutant mice (20% of the expected number;
Table 1). We presume that the deficit can be attributed to
maternal cannibalism of dead mutant neonates, because we
found that Gpc3/ and Gpc3/ embryos were alive and
present at the expected frequency at e18.5 (data not shown).
We note that, even in pure 129 strain background, lethality
in the absence of GPC3 is not 100%, as two of the three
recovered Gpc/ neonates reached adulthood and ap-
peared to be healthy. However, because of the viability
problem, attempts to obtain double mutants lacking both
GPC3 and IGF2 in a pure 129 strain background were
unsuccessful.
It is interesting that apparently different adverse modifi-
ers affect the perinatal lethality associated with lack of
GPC3, which was increased not only in a pure 129 back-
ground (our results), but also in a background significantly
enriched in B6 component (Cano-Gauci et al., 1999), in
contrast with the improved survival in hybrid states. How-
ever, some of the perinatal deaths previously reported
(Cano-Gauci et al., 1999) were clearly due to a high inci-
dence of respiratory infections attributed to presumptive
abnormalities of the bronchi and the respiratory epithe-
lium. We think that these deaths were unrelated to genetic
causes, as we found no evidence of abnormal lung develop-
TABLE 1
Breeding Data
Cross Sex Genotype
No. of mice
recovered
Observed
frequency
Expected
frequency Stillborn
Addional deaths
before weaning
G/II M or F W 22 0.208 0.250
M or F II/p 27 0.255 0.250 2 1
M G/ 15 0.141 0.125 1 1
M G/II/p 14 0.132 0.125 3 6
F G/ 17 0.160 0.125
F G/II/p 11 0.104 0.125
G/I M W 12 0.0769 0.0625 1
M I/ 9 0.0577 0.0625 4 3
M I/ 30 0.192 0.125
M or F G/ or G/ 20 0.128 0.125 2
M or F G/I/ or G/I/ 8 0.0513 0.125 4 4
M or F G/I/ or G/I/ 33 0.212 0.250 4 1
F G/ 14 0.0897 0.0625 3
F G/I/ 3 0.0192 0.0625 1 1
F G/I/ 27 0.173 0.125 1
G/R M W 7 0.067 0.0625 1
M R/ 2 0.019 0.0625 2
M R/ 16 0.154 0.125
M or F G/ or G/ 14 0.135 0.125 1 2
M or F G/R/ or G/R/ 7 0.067 0.125 7
M or F G/R/ or G/R/ 24 0.231 0.250 2 6
F G/ 11 0.106 0.0625
F G/R/ 6 0.058 0.0625 6
F G/R/ 17 0.163 0.125
G/H M W 23 0.150 0.125 2
M Hm/ 23 0.150 0.125 1
M or F G/ or G/ 35 0.229 0.250 4 5
M or F G/Hm/ or G/Hm/ 27 0.176 0.250 19 5
F G/ 20 0.131 0.125 1
F G/Hm/ 25 0.163 0.125 3 1
129 M or F W 41 0.672 0.500
M G/ 3 0.049 0.250 1
F G/ 17 0.279 0.250
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ment or respiratory infections in the analogous 129B6
hybrids that we have studied. Whether maintenance of our
mice in a pathogen-free barrier facility could explain this
discrepancy remains unknown.
It is notable that the incidence of perinatal death is quite
high for SGBS patients (in a total of 92 informative cases,
deaths of 17 neonates, including 1 stillborn, were described;
18.5%; see Lin et al., 1999). It is also notable that absence of
GPC3 in combination with overexpression of IGF2 (Gpc3/
or Gpc3/ mutants also carrying a maternally derived
H19 mutation) results in a highly significant incidence of
stillborn progeny (19/27; 70%; P  0.00025; Table 1),
whereas neither one of the single mutations causes neona-
tal death at a frequency higher than random.
FIG. 1. Targeting of the mouse Gpc3 locus and molecular analyses of mutants. (a) The restriction map in the region of exon 1 (black
rectangle) of the Gpc3 gene (top), the targeting construct (middle) used for gene disruption by homologous recombination (denoted by large
X symbols), and the structure of the derived targeted allele (bottom) are shown. The transcriptional orientation of the neo cassette (replacing
the deleted exon 1 and flanking sequences) is the same as that of the Gpc3 gene. An open rectangle and a wavy line represent a diphtheria
toxin (DT) gene cassette and plasmid vector sequence, respectively. Restriction sites are: HindIII (H), EcoRI (R), BglII (B), EagI (E), and KpnI
(K). The position of the probe (a 0.7-kb HindIII fragment located in the Gpc3 locus downstream from the 3 region of homology present in
the vector) that was used for Southern analyses of ES cell clones and mice is indicated, and the sizes (in kb) of the endogenous and targeted
EcoRI genomic DNA fragments recognized by this probe are shown. (b) Example of Southern analysis of EcoRI-digested tail DNA from
wild-type (lanes 1, 2, and 6) and Gpc3/ heterozygous females (lanes 3–5 and 7). The blot was hybridized with the probe shown in (a). (c)
Northern analysis of total RNA (30 g per lane) isolated from wild-type primary embryonic fibroblasts (lane 5; positive control) or e12.5
embryos of the following genotypes: wild-type (lane 1), double Gpc3//Igf2/p mutant (lane 2), single Igf2/p mutant (lane 3), and single
Gpc3/ mutant (lane 4). The blot was hybridized with a Gpc3 cDNA probe (see Materials and Methods), which detected a single 2.3-kb
Gpc3 mRNA species in the samples from wild-type and Igf2 mutant embryos (lanes 1 and 3, respectively), whereas a hybridization signal
was undetectable in the samples from embryos carrying the Gpc3 mutation (lanes 2 and 4), even after overexposure of the membrane
(middle panel). A picture of the gel (bottom panel) displaying the 18S and 28S ribosomal RNA species stained with ethidium bromide
indicates that approximately equal amounts of RNA were loaded per lane. In the top panel, the positions of these RNAs (size markers) are
indicated with arrows. (d) Western analysis of serum from e18.5 embryos (5 l per lane) used to assay relative amounts of IGF2 (bottom)
using -fetoprotein (AFP) as a standard (top). The specificity of the assay is indicated by the absence of immunoreactive IGF2 in sera from
Igf2 null mutants (lanes 3 and 6), in contrast with wild-type (lane 4) and Gpc3 mutant (lanes 1, 2, and 5) embryos. Results are also presented
for H19 and Gpc3/H19 mutants (lanes 7 and 8, respectively). Differences in the amounts of immunoreactive IGF2 were not detected
between the positive samples. In regard to the H19 specimen, the result is in agreement with previous data (the level of IGF2 is normal
in the serum of H19 mutants, in contrast to a twofold increase detected in embryonic tissues; Eggenschwiler et al., 1997).
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FIG. 2. Body size, pigmentation defects, and skeletal abnormalities of mutant mice. (a) Example of body-size phenotypes of wild-type (W)
neonates and mutant littermates lacking GPC3 (G), IGF2 (II), or both (G/II). (b) p15 wild-type (W) and Gpc3/ (G) siblings. The mutant,
which is smaller than wild-type at this age (see text), lacks pigmentation in the feet and the distal third of the tail. (c) White belly spotting
in a Gpc3/ mutant. (d, e) Postaxial polydactyly (arrows) in e18.5 embryos affecting only a forelimb (d) or both a forelimb and a hindlimb
(e). (f) Agnathia in a stillborn Gpc3/ mutant [absence of the mandible and presence of only a small skin bud (arrow) in its place]. (g, h) Ribs
and sternum of e18.5 wild-type (W) and Gpc3//H19 double mutant (G/H) embryos. The skeletons were stained with Alizarin red and Alcian
blue. In the mutant, articulation between the sternum and the ventral tips of the costal cartilages has occurred asymmetrically and in a
staggered fashion on opposite sides, resulting in ossification of sternal segments (h; arrow), in contrast to wild type (g; arrow). The sternum
of the mutant is broader than normal and has a bifurcating xiphoid process (arrowhead). (i, j) The top two ribs of the double mutant shown
in (h) are fused in their middle portions, but attached separately to the spine (i; arrow) and to the sternum (j; arrow). (k) The body of each
lumbar vertebra in the skeletal preparation of a wild-type embryo has a single ossification center (arrow). (l) Twin ossification centers are
present in the bodies of the L2–L6 lumbar vertebrae of the same Gpc3
//H19 double mutant embryo as in (h). The ossification center in
L1 is normal, but this vertebra possesses an extra (14th) pair of rudimentary ribs (arrowhead). (m, n) In Igf1r/ single mutant embryos (R;
e18.5), the tibia is positioned at a right angle to the calcaneous (lines), as in normal mice. (o, p) Some double mutants lacking both GPC3
and IGF1R (G/R) exhibit a deformity resembling a club foot (the calcaneous is not positioned at an angle with respect to the tibia; lines).
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FIG. 3. (a–d) Intestinal abnormality in Gpc3 mutants. An example of severe gaseous abdominal distension in a mutant neonate is shown
in (a). The typical appearance of gas bubbles in the intestine after dissection of a p5 pup is displayed in (b) and, in blowup, in (c). (d) Gaseous
inflation of the cecum in a p15 mutant. (e–i) Spleen phenotypes. The spleen and accessory spleen (arrow) of a Gpc3 mutant is shown in
(e). Sections of wild-type (f, h) and Gpc3 mutant (g, i) spleens from p15 (f, g) and p170 (h, i) mice are compared at low and high
magnification, respectively. The mutant spleen is small and, at an advanced age (p170), exhibits a relative enlargement of follicles in an
anastomosing pattern (arrow). (j–m) Renal phenotypes. Sections of kidneys from a wild-type neonate (j, k) and a stillborn Gpc3 mutant (l,
m) are compared in low (j, l) and high magnification (k, m). In the mutant, cystic dysplasia is evident in both the renal cortex and the
medulla. The inset in (m) displays a hydronephrotic mutant kidney (cf. k, inset). (n–r) Placental phenotypes. The sections of e18.5 placentas
are from: wild-type embryo (n), Gpc3 mutant (o), H19 mutant (p), and Gpc3//H19 double mutant (q). The macroscopic appearance of
the placentas in (n–q) prior to sectioning is shown (in the same order, from top to bottom) in (r). The bar corresponds to 1 cm. (s) In situ
hybridization analysis of Gpc3 expression in e17.5 wild-type placenta. Sections were hybridized with an antisense (top, and blowup in the
middle) or a sense (control) probe (for details, see text). (t) e16.5 H19 mutant embryo. (u) A Gpc3//H19 double mutant littermate of the
embryo in (t) exhibiting ompalocele.
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Pigmentation defects. The majority of mice lacking
GPC3 (50/62; 80%) lacked pigmentation in their feet and in
the distal third of their tails (Fig. 2b; the latter feature was
detectable, despite tail clipping for genotyping). Interest-
ingly, the same abnormalities were observed in Gpc3/
females, but at a lower frequency (15/58; 26%). In addition,
10% of the Gpc3/ or Gpc3/ and 2% of the Gpc3/
mice (6/62 and 1/58, respectively) exhibited white belly
spotting (Fig. 2c). The patch of white fur, which was not
particularly extensive, was confined to the ventral side
around the umbilicus and had sharp borders (intermingling
with pigmented hairs was not observed).
These pigmentation defects, which were absent from
wild-type siblings, suggest that during embryogenesis
GPC3 may play some role in neural crest derivatives,
making contributions to pigmented tissue (melanocytes) in
the trunk. Hypopigmentation has been attributed to failure
of neural crest cells to colonize those areas of the skin that
are the last to receive migrating melanoblasts (Rawles,
1947). The white-spotting phenotype could be the conse-
quence of defects in the migration, differentiation, or sur-
vival of melanocytes. Gpc3 is highly expressed in the
paraxial mesoderm surrounding the neural tube, but not in
the neural tube itself (Pellegrini et al., 1998). Therefore, one
possibility is that GPC3 interacts with extracellular factors
that provide directional or survival signals for the neural
crest cells as they migrate through mesenchyme.
Skeletal defects. A low incidence of polydactyly and
rare occurrence of agnathia were observed in mutants
lacking GPC3, but other obvious abnormalities were not
detected in skeletal preparations (n  7) of e18.5 embryos.
Notably, cleft palate, a feature observed quite frequently in
SGBS, was never detected in our mutant mice either by
additional analysis of histological sections (n  12) or by
examination of many mutant animals during autopsy.
The observed polydactyly was always postaxial (Figs. 2d
and 2e) and was manifested with incomplete penetrance
(6/79 mutants were affected; 7.6%). It affected mostly the
forelimbs, but cases with extra digits appearing in both
forelimbs and hindlimbs (Fig. 2e) or exclusively in hind-
limbs were also observed. Polydactyly was described in
18/73 (25%) SGBS cases (for references, see MIM 312870
and Garganta and Bodurtha, 1992) and was also mostly
postaxial (12/18). Apparently, polydactyly was not observed
in the Gpc3/ mutants described previously (Cano-Gauci et
al., 1999; Paine-Saunders et al., 2000). However, Gpc3/
hemizygotes that were also heterozygous for the gene-
encoding bone morphogenetic protein 4 (Bmp4/) exhib-
ited postaxial polydactyly with 100% penetrance and vari-
able expressivity (Paine-Saunders et al., 2000), whereas only
12% of the Bmp4/ mutants were found to be polydac-
tylous (manifesting preaxial polydactyly of the right hind-
limb; Dunn et al., 1997). The combination of BMP4 haplo-
insufficiency and lack of GPC3 not only increased the
severity and changed the pattern of polydactyly from pre-
axial to postaxial but also resulted in manifestation of
sternal and rib malformations not observed with either
mutation alone (Paine-Saunders et al., 2000). Although
these results did not reveal mechanistic details, some kind
of interaction between two signaling pathways was im-
plied. We think that this is an example of a phenomenon
known as “emergenesis” or “digenic inheritance” (emer-
gence of novel phenotypic features in compound mutants
carrying independently segregating mutant alleles; see Ka-
jiwara et al., 1994; Helwig et al., 1995; De Arcangelis et al.,
1999).
An additional skeletal deformity manifested in 2/79
(2.5%) of our mutants was agnathia, i.e., complete absence
of the mandible (only a small bud of skin was present
instead of the lower jaw; Fig. 2f). This trait also appeared in
10% of other Gpc3/ mutants after extensive backcrossing
into the B6 background (Cano-Gauci et al., 1999). The
observed agnathia was all-or-none, as we did not encounter
a variable degree of mandibular hypoplasia (micrognathia).
In this regard, the Gpc3 mutants differ from Smad2/mh1
heterozygous mutants, 10% of which exhibited variable
degrees of hypoplasia up to complete absence of the man-
dible (Nomura and Li, 1998). It is notable that conditional
inactivation of Fgf8 in the mesenchyme of the first
branchial arch that is derived from the neural crest results
in severe craniofacial defects, including agnathia (Trumpp
et al., 1999).
Double mutants carrying a combination of the Gpc3 and
H19 mutations exhibited skeletal defects, predominantly
of the sternum, which were not observed in either of the
single mutants (Fig. 2h). The normal, fully developed ster-
num consists of six ossified segments: the manubrium, four
sternebrae, and the xiphoid process (xiphisternum) remain-
ing cartilagenous in its lower part. This segmentation
results from the attachment of ribs (of 13 ribs, 7 attach to
the sternum). The sternum develops from e12 onward from
a pair of parallel condensations (bands) derived from migrat-
ing lateral plate mesodermal cells (Chen, 1952; Kaufman,
1992; Kaufman and Bard, 1999). The bands extend caudally,
move ventromedially, and eventually fuse with each other
in the midline in a craniocaudal sequence. They differenti-
ate into cartilage by e16.0. Subsequent differentiation of
cartilage into bone commences from ossification centers in
the sternal segments that become well-ossified by the time
of birth and are separated by cartilage where the ribs make
contact. The most ventral parts of the ribs, which do not
ossify but differentiate into costal cartilages, inhibit the
hypertrophy of cartilagenous cells of the sternum near the
sites of their attachment (in appearance, there is an impres-
sion that costal cartilage crosses the sternum; Fig. 2g,
arrow). If the attachment of ribs to the sternum occurs in a
slightly asymmetrical fashion, the sternebrae become cor-
respondingly oblique. This variation (not true abnormality),
which is described as “crankshaft-sternum” (Theiler, 1989),
was consistently observed (4/4) in skeletal preparations of
single Gpc3/ mutants (not shown). In the Gpc3 and H19
double mutants, however, the ordered pace of the develop-
mental events described above was apparently disrupted
more severely. As in other analogous cases, articulation
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between the sternum and the ventral tips of costal carti-
lages occurred asymmetrically in a staggered fashion, thus
allowing undue ossification and fusion of sternal segments.
This has been observed as a consequence of experimental
amniotic sac puncture performed at e12.5–e13.5 (Chang et
al., 1996), and in mutants lacking myogenin (Hasty et al.,
1993; Vivian et al., 1999), ETL1 (a SWI2/SNF2 family
member; Schoor et al., 1999), ZIC1 (a zinc finger transcrip-
tion factor; Aruga et al., 1999), EF1 (a zinc finger and
homeodomain transcription factor; Takagi et al., 1998) and,
interestingly, heparan sulfate 2-sulfotransferase (an enzyme
catalyzing the transfer of sulfate to the iduronic acid com-
ponent of heparan sulfate; Bullock et al., 1998). The same
phenotype (staggered attachment of ribs and ossification of
the sternum throughout its length; Fig. 2h, arrow) was
observed in 3/6 skeletal preparations of Gpc3 and H19
double mutants that we examined. In the same mutants,
the cartilage of the xiphisternum was bifurcated (Fig. 2h,
arrowhead), whereas in the remaining three specimens of
double mutants, a “punched-out” hole was observed in the
cartilagenous part, a feature that is not considered as an
abnormality (see Kaufman, 1992). In the latter skeletons,
the abnormal, excessive ossification did not involve the
entire sternum, but was confined to the region between one
or two pairs of attached costal cartilages. In one of these
cases, the sternum was also split vertically in the region
extending between ribs 4 and 7, suggesting local failure of
fusion between the sternal rudiments.
In addition to sternal defects, one severely affected Gpc3
and H19 double mutant animal exhibited unilaterally a
fusion of the first two ribs in their middle portion (they
were separately attached to the spine and the sternum; Figs.
2i and 2j). The same mutant also possessed an extra (14th)
pair of rudimentary ribs (Fig. 2l, arrowhead) associated with
the first pair of lumbar vertebrae (L1), whereas the body of
the remaining vertebrae in the lumbar region (L2–L6) exhib-
ited two (bilateral) ossification centers (Fig. 2l, arrow),
rather than a single one in the middle (Fig. 2k) as normally
observed (no defects were detected in the ossification cen-
ters of the vertebral arches). In addition to the emergenesis
affecting their skeleton, the Gpc3 and H19 double mu-
tants exhibited a high incidence of omphalocele, a trait
never observed in animals carrying either of the single
mutations of the compound genotype (omphalocele was
manifested in 13/16 double mutant embryos examined at
e16.5; cf. Figs. 3u and 3t). Although umbilical hernias
appear quite frequently in SGBS patients, the occurrence of
omphalocele is rare, in contrast to BWS (reviewed by
Eggenschwiler et al., 1997).
Unexpectedly, still another phenomenon of emergenesis
was encountered in double mutants lacking both GPC3 and
IGF1R. When examined at e18.5, 9/14 of these double
mutant embryos exhibited a hind limb defect resembling
club foot (Figs. 2o and 2p). Specifically, the hind paws were
abnormally bent medially with respect to the axis of the
tibia. Normally, the bones of the tibia and fibula are
approximately positioned at a right angle to the calcaneus
(Figs. 2m and 2n). Examination of skeletal preparations
from two of the Gpc3 and Igf1r double mutants indicated
that the calcaneus was not positioned at an angle with
respect to the tibia (cf. Figs. 2p and 2n). Occurrence of
clubfoot (but also clubhand) has been observed in embryos
after experimental amniotic sac puncture performed at
e12.5–e13.5 (see Kaufman and Chang, 2000). Analogous
observations were made with the mouse mutant cl (club-
foot; Robins, 1959). We also note that 30% of Smad3
nullizygotes exhibit medially torqued wrist joints and, less
frequently, ankle joints (Datto et al., 1999). Clubfeet have
been described in three SGBS patients (Hughes-Benzie et
al., 1996; Kim et al., 1999).
Intestinal abnormality. A striking, quite frequently ob-
served phenotypic feature of mutant neonates lacking
GPC3 was the presence of intestinal gas resulting in ab-
dominal distension that was occasionally severe (Figs. 3a–
3d). Upon dissection, the gas was usually localized in the
ileum, but was also found throughout the entire length of
the small and large intestine (sometimes including an
inflated cecum; Fig. 2d). However, presence of gas in the
stomach was not observed. In this regard, the condition of
the Gpc3 mutants apparently differs from the insufflation
of the entire gastrointestinal tract due to accumulation of
air that was described in mouse neonates with feeding
and/or breathing difficulties carrying, for example, targeted
mutations of the genes Hoxa3 (Chisaka and Capecchi,
1991), Hoxa2 (Gendron-Maguire et al., 1993), goosecoid
(Rivera-Pe´rez et al., 1995; Yamada et al., 1995), etc., or
gain-of-function Msx2 transgenes (Winograd et al., 1997). In
the latter case, in which the gaseous abdominal distension
was associated with a variable degree of micrognathia and
cleft secondary palate, it was thought that glossoptosis
(posterior malpositioning of the tongue within the cleft in
conjunction with the micrognathia) led to airway obstruc-
tion and insufflation of the gastrointestinal tract. An analo-
gous respiratory malfunction, which results in swallowing
of air during suckling that subsequently reaches the stom-
ach and the intestines in large amounts, was described in
mutants of the unidentified locus bradypneic (Green and
Jahn, 1977).
In the case of Gpc3 mutants, the gaseous abdominal
distension was consistently correlated with runting. In the
most severe cases, the mutants were significantly growth-
retarded and moribund, but animals affected less severely
were able to survive. In such cases, the gas had dissipated by
p18. More detailed analysis at two ages (e18.5 and p15)
indicated that the accumulation of gas was not associated
with other intestinal abnormalities. Thus, the length and
weight of the intestine were normal in the Gpc3 mutants
and examination of cross-sections at 1-cm intervals failed
to reveal histological differences from the controls (data not
shown). Moreover, comparative immunohistochemical
analysis of intestinal sections using several neuronal mark-
ers confirmed the presence of myenteric plexi in both
mutants and controls (not shown). Thus, the presumptive
neural crest defect resulting in pigmentation abnormalities
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in the Gpc3 mutants was not accompanied by overt anoma-
lies of the enteric nervous system, in contrast to other
mouse mutations causing coat-color spotting and megaco-
lon (see Gershon, 1999).
The cause of abdominal bloating when GPC3 is lacking
remains unknown. The condition is not associated with
reduced gastrointestinal motility, while the absence of
gastric involvement suggests that occurrence of aerophagia
(swallowing of air) is rather unlikely. Analysis of postnatal
growth (see below) has shown that all mutant mice, includ-
ing those without an abdominal distension, grow with a
reduced rate before weaning, although they are fed (suckling
is successful and milk can be seen in the stomach of
mutants in amounts comparable to those present in control
siblings). Because the growth retardation of mutants is
transient, it is likely to be due to malnutrition resulting, for
example, from insufficiency of digestive enzymes. During
the suckling period, intestinal lactase displays high activity
making the neonates capable of digesting lactose in the
milk. This activity then declines, while maltase, sucrase,
and other enzymatic activities appear or rise at weaning
(see, for example, Aubin et al., 1999). Preliminary measure-
ments at p7 of intestinal disaccharidase activities in ran-
domly selected Gpc3 mutants (n  3) and wild-type mice
(n  4) indicated that the lactase activity was approxi-
mately twofold lower in the mutants (9.2 	 2.0 units vs.
17.5	 3.0 in the controls). In contrast, the still low levels of
maltase activity were similar in mutants and controls
(14.57 	 1.2 and 12.45 	 1.7, respectively), whereas the
sucrase activity was practically undetectable in the wild-
type mice and barely detectable (1.2 	 0.3 units) in the
mutants. It remains to be seen whether the reduction of
lactase in the mutants could be correlated with fermenta-
tion of undigested lactose by the intestinal flora and pro-
duction of excess gas (hydrogen, carbon dioxide, and vola-
tile short-chain fatty acids).
We note that measurements of blood glucose levels were
consistent with the notion that the preweaning growth
retardation observed in Gpc3 mutants could be caused by
malnutrition (although alternate interpretations for the
observed correlation between hypoglycemia and low
weight, which is described below, cannot be excluded). At
p1, i.e., at a time when the Gpc3 mutant neonates were still
larger than their normal siblings (2.32 	 0.1 g, n  9 vs.
1.77 	 0.04 g, n  6), a difference in glucose concentration
was not detected (71.0 	 2.8 and 76.8 	 4.4 mg/dL for
mutants and controls, respectively). At p15, however, when
two nonoverlapping body weight groups of Gpc3 mutants
were examined (exhibiting either low or close to normal
weights), the situation was different. Whereas the blood
glucose concentration in the mutants that were not se-
verely affected (average weight 8.95	 0.9 g; glucose 130.6	
9.0 mg/dL; n  7) did not differ from that of controls
(10.95 	 0.7 g; glucose 122.3 	 6.7 mg/dL; n  10), the
severely growth-retarded mutants (4.5 	 0.3 g; n  7) were
markedly hypoglycemic (glucose 51.7 	 4.2 mg/dL).
Microsplenia and accessory spleens. Gross examina-
tion during autopsy indicated that the spleens of Gpc3
mutants were smaller than normal (cf. Figs. 3f and 3g).
Further analysis indicated that the mutant spleen exhibited
a negative allometric relationship to body weight (the
average spleen to body weight ratio did not exceed60% of
the normal value; data not shown). This was surprising
because the spleen phenotype, which was not described
previously for Gpc3 mutants (Cano-Gauci et al., 1999;
Paine-Saunders et al., 2000), is opposite to the frequently
described “splenomegaly” detected in SGBS patients by
clinical examination. We note, however, that in one case
with an available autopsy record (Opitz et al., 1988), the
spleen was 100 g, which, according to our calculations (for
formulas, see Kock et al., 1997), was normal for the age (25
months) and body weight (estimated to be 20 kg) of the
patient.
Despite a significant reduction in spleen size correlating
with a histologically detectable decrease in follicular di-
mensions and level of hemopoietic activity, abnormalities
in the architectural arrangement of the white and red pulp
compartments were not observed in stillborn Gpc3 mutants
(n  2; compared with 4 wild-type controls) or in mutants
sacrificed at p15 (n  4; compared with 8 controls). More-
over, preliminary flow cytometric analysis indicated that
the correct populations and proportions of B and T cells
were present in the mutants (data not shown). However,
histopathological examination of mutant spleens at 6
months of age (n  4; compared with 5 controls) demon-
strated an apparent enlargement of follicles present in a
complex anastomosing pattern (Fig. 3i), in contrast to the
discrete and evenly sized normal counterparts in the con-
trol specimens (Fig. 3h).
We note that, in several Gpc3 mutants, we observed the
presence of accessory spleens associated anatomically with
the tail of the pancreas (Fig. 3e, arrow). Although such
ectopic splenic tissue separate from the main body of the
spleen was not detected in any of the wild-type animals that
we have examined, it is not straightforward to assign this
feature as part of the Gpc3-null phenotype, as accessory
spleens can be found in normal mice as a variation. In fact,
sometimes they are present at a very high, strain-dependent
frequency (for example, 30% of C57BL/6 mice possess
accessory spleens; Hummel et al., 1975). Similarly, the
occurrence of one or more such supernumerary spleens,
which should not be confused with polysplenia (presence of
multiple, small spleens instead of a single regular one), has
been occasionally described in SGBS patients (Opitz, 1984;
LeMerrer et al., 1989; Chen et al., 1993), but this usually
asymptomatic feature is found in at least 10% of unrelated
autopsies (see Freeman et al., 1993).
Renal dysplasia. Previously, the manifestation of renal
cystic abnormalities in the absence of GPC3 was either
described briefly (Paine-Saunders et al., 2000) or studied in
great detail in Gpc3 mutants of the N4 backcross onward
(Cano-Gauci, 1999; Grisaru et al., 2001). Therefore, our
account of the kidney phenotype need not be extensive and
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it will be mainly focused on differences from the previous
reports that described the observed dysplasia as confined to
the renal medulla. In contrast, we have also detected cystic
changes in the renal cortex (cf. Figs. 3l and 3m with Figs. 3j
and 3k). The reason for this discrepancy is unknown and, in
our view, cannot be attributed to strain differences (we
examined F2 hybrids rather than progeny of backcrosses), as
it concerns only the topography and not the nature of these
lesions.
Overall, in agreement with previous observations (Cano-
Gauci et al., 1999), we found extensive variability in the
degree of severity of this dysplasia, which appeared to
correlate with mortality. Thus, we did not encounter sig-
nificant histopathological findings in the particular embry-
onic specimens (e16.5–e18.5) that we examined (n  3),
whereas in stillborn mutants (n 7), we observed dilatation
of renal tubules throughout the kidneys with a variable
degree of severity. Scattered small tubular cysts correspond-
ing predominantly to proximal tubules (with less involve-
ment of distal tubules) were found in both the renal cortex
and medulla and were most prominent in the proximity of
the junction between these regions (Fig. 3m). At p15, we
observed consistently that the renal cortex was thinner in
the mutants (n  4) than in the controls (n  2). This
aberration was accompanied by an apparent expansion of
the medulla in the form of irregular clusters of distal
tubules protruding unevenly beyond the medulla into the
renal cortex to variable levels (not shown). In long-lived
survivors, however, the kidney abnormalities were not very
prominent. Thus, in 6-month-old mice, only a slight
distension of the medullary collecting ducts was evident in
the mutants (n  3), in comparison with the controls (n 
3), whereas tubular cysts were absent. In a single mutant,
the collecting duct abnormality was associated with mild
dilatation of the renal pelvis, consistent with early hydro-
nephrosis (not shown). Although we did not keep a detailed
record, we note that, in contrast to wild-type mice, hydro-
nephrotic kidneys were observed upon dissection of several
adult mutants that were sacrificed because they were found
in distress with distended abdomens. Usually, only one of
the kidneys was enlarged and filled with clear fluid (Fig. 3m,
inset; cf. Fig. 3k, inset). The exact site of the presumptive
obstruction for the development of hydronephrosis remains
unknown.
In addition to somatic overgrowth, the renal phenotype of
Gpc3 mutants is the closest feature also listed among the
hallmarks of SGBS. Overall, nephromegaly has been de-
scribed in 19/73 cases (for references, see MIM 312870 and
Garganta and Bodurtha, 1992). Hydronephrosis was noted
in 3/19 cases, while the kidneys were characterized as
“dysplastic” and/or “cystic” in 10/19 cases. However, au-
topsy details have been reported only twice. “Renal dyspla-
sia” is a descriptive term implying abnormal kidney mor-
phogenesis that is used without histopathological
discrimination for a diverse group of renal disorders (see
Matsell, 1998). Most dysplasias, however, are associated
with the presence of greatly dilated tubules (cysts). The
cystic changes described in one of the SGBS autopsies
(4-month-old patient) involved both tubules and glomeruli
(Golabi and Rosen, 1984), while in the second available
autopsy (death occurred at the age of 3 days), the presence of
“bilateral peripheral cortical cystic renal dysplasia” was
recorded (Chen et al., 1993). Accordingly, the cortical and
medullary cystic abnormalities that we observed in our
Gpc3 mutants are seemingly at least analogous to the
limited observations from SGBS patients.
Placentomegaly. Although most of the SGBS records do
not include descriptions of the placenta, significant placen-
tomegaly was reported in two cases (Hughes-Benzie et al.,
1994; Yamashita et al., 1995). The weights of these placen-
tas were 900 and 1110 g, i.e., 30 and 60% higher than the
normal average of 680 g (see Hindmarsh et al., 2000).
Analogous placentomegaly was observed in Gpc3 mutant
mice. Thus, the e18.5 placentas of embryos lacking GPC3
(0.1139 	 0.0027 g; n  16) were 38.6% heavier than those
of the controls (0.0822 	 0.0026 g; n  13), whereas a
dramatic increase in weight was observed in the placentas
of Gpc3/H19 double mutants (0.1595 	 0.0047 g; n  24),
which were 94% heavier than normal. Considering that the
placental weight of single H19 mutants (0.1282 	 0.0035
g; n  5) was 56% higher than normal, it is interesting that
the combined effects of excessive IGF2 (due to the H19
mutation) and absence of GPC3 in the double mutants were
exactly additive (56  38.6  94.6%). These differences in
placental weights (wild-type  Gpc3/ or Gpc3/ 
H19  double mutant) could be attributed predominantly
to corresponding differences in placental disc diameters (see
Fig. 3r) with smaller, but easily detectable differences in
thickness, especially in the case of the double mutant (see
Figs. 3n–3p). However, the overall architectural and cyto-
logical appearances of the decidua, spongiotrophoblast, and
labyrinthine layers were preserved in the mutants, except
that the incremental gains in thickness were due to expan-
sion of the labyrinth, whereas the width of the spongiotro-
phoblast did not differ from wild type (Figs. 3n–3p). Similar
observations, based both on weight measurements and
histological analyses, were made for e16.5 placentas of all
four genotypes described above (data not shown). The
placentas lacking GPC3 were also 22% heavier than wild
type at e14.5 (the earliest time point that we have exam-
ined; 0.1059 	 0.0026 g, n  30 vs. 0.0866 	 0.0042 g,
n  15).
Considering that a known effect of IGF2 excess is hyper-
plasia (see, for example, Ludwig et al., 1996; Eggenschwiler
et al., 1997), and assuming that lack of GPC3 has (indi-
rectly) similar consequences, it is likely that the increased
placental size observed in the single and double mutant
specimens, in which overt histopathological findings were
absent, is due to hyperproliferation, potentially through
paracrine actions. It is notable, in this regard, that in situ
hybridization analysis of Gpc3 expression in normal e17.5
placentas demonstrated the presence of intense signal in all
cells of the yolk sac and an additional less intense signal in
an arborizing pattern restricted to mesenchymal cords of
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the labyrinthine trabeculae, whereas adjacent trophoblastic
and endothelial cells were negative for hybridization (Fig.
3s). On the other hand, Gpc3 expression was undetectable
in the spongiotrophoblast, i.e., in the placental zone that
does not expand in the mutants (Fig. 3s). Expression of Igf2
in the rodent placenta analogous to that of Gpc3 has been
detected in the yolk sac and in the trabeculae of the
labyrinth (Zhou and Bondy, 1992; Redline et al., 1993;
Correia-da-Silva et al., 1999). In contrast to Gpc3, however,
Igf2 is expressed in the entire mouse placenta, i.e., in both
the spongiotrophoblast and labyrinthine zones (Redline et
al., 1993), and also in the structurally homologous regions
of the human placenta, the extravillous trophoblast, and the
floating chorionic villi, respectively. More specifically, hu-
man IGF2 is expressed in the mesodermal core and the
surrounding villus cytotrophoblasts, but not in the villous
syncytiotrophoblast sheath (reviewed by Han and Carter,
2000). In contrast, both the syncytiotrophoblast and cy-
totrophoblast layers of the villi express GPC3 at high and
low levels, respectively, whereas expression is undetectable
in the mesenchymal elements (Khan et al., 2001). These
apparent differences between the human and mouse pat-
terns of placental Gpc3 expression require further investi-
gation.
Embryonic and Postnatal Growth of Mutants
During development, increase of the mammalian organ-
ism in size (growth) is brought about predominantly by
proliferative events increasing cell number rather than cell
size. In fact, measurements of cell sizes or counting the
number of cell nuclei present within a length of 100 m in
sections of heart, kidney, and liver of p15 Gpc3, H19, and
Gpc3/H19 mutants did not reveal statistically significant
differences from wild type (data not shown).
The rate and duration of the proliferation that determines
the growth process are reflected in a progressive weight
increase until a final body size is attained when a state of
balance between proliferation and apoptosis is reached.
Thus, growth curves (plots of weight vs. developmental age)
and their derivatives (plots of growth rates) can provide a
relatively coarse, but informative index in comparing
growth patterns between mutant and wild-type mice.
Statistical analysis of weight data of wild-type and mu-
tant embryos lacking GPC3 at various embryonic days
indicated that the overgrowth of mutants was undetectable
at e11.5 (0.0414 	 0.0017 g, n  4 for mutants vs. 0.0366 	
0.0009, n  4 for wild-type controls). However, a statisti-
cally significant difference became evident from e12.5 on-
ward (the weights for mutant and control embryos at e12.5
were, respectively, 0.1416 	 0.0066 g, n  9; 0.1113 	
0.0045 g, n  11). At e18.5, the mutant mice were 30%
heavier than normal (1.77 	 0.025 g, n  44 vs. 1.35 g, n 
27), in agreement with previous reports (Cano-Gauci et al.,
1999; Paine-Saunders et al., 2000).
Interestingly, when the Gpc3 and H19 mutations were
combined, there was no additivity in the excess in embry-
onic weights, in contrast to the results that we described
above for the placenta (see Concluding Remarks, for a
discussion of this difference). Thus, the weight of e18.5
mutants lacking GPC3 (1.77 g, as reported above) was the
same as that of H19 mutants (1.70 	 0.06 g, n  5) and
double mutants (1.70 	 0.03 g, n  25).
To study postnatal growth, we compared growth curves
(representing cumulative weight at a given time) derived by
regression analysis of a robust set of primary weight data
(Figs. 4a and 4b). From this analysis, a difference between
sexes in wild-type controls was detected only shortly after
weaning (p25), as expected (due to the emerging actions of
distinct gonadal steroids during the period of pubertal
growth spurt). Exactly the same gender-specific growth
patterns were observed in mutants lacking GPC3 (Gpc3/ or
Gpc3/).
The growth-spurt period is reflected clearly in a graph of
absolute growth rate (absolute weight gain per unit time),
which is biphasic (Fig. 4c). Although the cumulative weight
of a mouse continues to increase during the approximate
time interval between p10 and p15 (Fig. 4a), it does so with
a lower rate than previously (Fig. 4c). However, after this
initial decline, the growth rate increases again starting at
p20 (growth spurt), but only transiently (it begins declin-
ing again at a time close to p30).
Unexpectedly, we observed that the p10–p15 decline in
growth rate was greater in Gpc3/ mutants than in wild-
type males, i.e., the mutants exhibited transient growth
retardation relative to the controls (Figs. 4c–4e; the same
was observed in a comparison between wild-type and
Gpc3/ females; data not shown). This phase, however,
was followed by a higher-than-normal rate in the mutants
during the period of the pubertal growth spurt (Fig. 4c).
These two growth phases could also be observed clearly
when the already attained weight at each time point was
used as a normalizing factor to convert absolute growth
rates to specific growth rates (Fig. 4d). At around p40, the
specific growth rates were practically indistinguishable
between mutants and controls and tended toward zero, as
the growth of animals of both genotypes was approaching a
steady state.
Because of the described relative growth retardation, the
cumulative weight of Gpc3/ mice, which was 120%N at
birth, began decreasing continuously, and between p14 and
p19 (Fig. 4e; see also Fig. 2b), the mutants were no longer
larger than the controls (in fact, they were slightly smaller
on average, and some of them at the low end of the weight
distribution exhibited significant runting). This decline in
relative weight was followed by a period of catch-up growth
(i.e., growth at an accelerated rate after an interval of
growth failure). Thus, by the end of the period of observa-
tion (p45), the mutants had acquired a relative weight that
was the same as that at birth (120%N). This relative
weight was maintained throughout adulthood. For ex-
ample, measurements at p170 showed that the weight of
Gpc3/ mutants was25% higher than that of normal mice
(41.1 	 1.63 g vs. 32.8 	 0.95 g; n  5 for each group).
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Interestingly, heterozygous Gpc3/ females possessing a
normal amount of GPC3 but in half of their cells (mosaics
because of random X-chromosome inactivation in the
soma), exhibited half the excess of body weight over wild-
type at p45 (110%N vs. 120%N in Gpc3/ females; see
Table 2). It is notable that female SGBS carriers exhibit
some degree of overgrowth and variably mild SGBS pheno-
typic features (Hughes-Benzie et al., 1992a). However, com-
plete manifestations of SGBS phenotypes have been de-
scribed in two females with X;autosome translocations
disrupting the GPC3 gene (Punnett, 1994; Pilia et al., 1996;
Hughes-Benzie et al., 1996). Apparently, as in other cases
with analogous translocations, skewing in X-chromosome
inactivation affected preferentially the structurally normal
X (see, for example, Krepischi-Santos et al., 2001, and other
references therein).
The cause(s) of transiently occurring relative growth
retardation and the mechanism of catch-up growth remain
unknown. One possibility is that the growth rate is briefly
reduced in the mutants because of malnutrition, since the
time window for this observation coincides with the intes-
tinal abnormalities that we have described. An analogous
FIG. 4. Growth analysis. (a, b) Average growth curves (derived as described in Materials and Methods) of male and female mice,
respectively. The genotypes were: wild-type mice (W), Gpc3/ or Gpc3/ mutants (G), Gpc3/ heterozygous females (G	), Igf2-null
(Igf2/p) mice (II), Gpc3//Igf2/p male double mutants (G/II), Gpc3//Igf2/p female double mutants (G	/II), and H19 (H) male
mutants. The number of animals of each genotype used to calculate average weights is shown in parentheses. The flags represent standard
errors. From the curves in (a), absolute growth rates (dW/dt) and specific growth rates [(dW/dt)  (1/W)] were calculated and are shown in
(c) and (d), respectively. The weight values of the curves in (a) were also used to calculate relative (% of normal) weights that are shown in
(e). In (f) and (g), available weight and height values, respectively, of SGBS patients are superimposed on standard growth charts for males
(values for the 50th, 75th, 90th, 95th, and 97th percentiles are represented, from bottom to top, by the curves and, in the insets, by dots).
Weight or height values for patients older than 20 years are lumped and positioned arbitrarily at a single time point between 250 and 300
months of age. In the insets, each dash represents the weight or height at birth of an individual SGBS patient (in some cases, dashes are
superimposed). The data are from: Simpson et al., 1975; Golabi and Rosen, 1984; Tsukahara et al., 1984; Behmel et al., 1984, 1988; Opitz,
1984; Opitz et al., 1988; Neri et al., 1988; LeMerrer et al., 1989; Ko¨nig et al., 1991; Hughes-Benzie et al., 1992a, 1994, 1996; Garganta and
Bodurtha, 1992; Gurrieri et al., 1992; Chen et al., 1993; Yamashita et al., 1995; Lapunzina et al., 1998; Kim et al., 1999; Savarirayan and
Bankier, 1999; Okamoto et al., 1999; Wabitsch et al., 2001.
198 Chiao et al.
© 2002 Elsevier Science (USA). All rights reserved.
situation has been observed, for example, in mice nullizy-
gous for the Mf3 gene (encoding a winged helix/forkhead
transcription factor), which exhibit early postnatal growth
retardation because of potential feeding defects but, if they
survive, grow with a normal rate after weaning (Labosky et
al., 1997). However, full restoration of body weight to
normal does not occur. In contrast, mice nullizygous for the
homeobox-containing gene Otx1 (apparently involved in
growth hormone gene expression, but only transiently)
become growth retarded during the first month of postnatal
life, but they recover completely by 4 months of age
(Acampora et al., 1998). Catch-up growth (for a review, see
Boersma and Wit, 1997) seems to be affected by some kind
of systemic compensatory action in response to a mecha-
nism apparently monitoring whole-body size and sensing
that a presumptive set-point appropriate for a particular age
has not been reached. In this regard, the example of the
Gpc3/ mutants is currently unprecedented, as it presum-
ably involves set-points in a growth trajectory that are
somehow adjusted to the level of overgrowth already at-
tained during embryogenesis. This is quite remarkable
because, at the time when the unknown cause of transient
growth retardation is eliminated, the size of the mutants
has become by default “normal,” and the expectation
would have been that they would continue to growth with
a rate equal to that of controls. Instead, for a time, they
grow with a rate that is higher than normal. Interestingly,
however, this process does not overshoot and there is no
overgrowth beyond the attainment of a relative body size
matching the one at birth. We surmise, therefore, that if the
transient growth retardation had not occurred, the Gpc3/
mutants would have grown with a normal rate and would
have maintained a 120%N relative size throughout their
postnatal development (i.e., they would have exhibited a
practically invariable pattern of relative body weight simi-
lar to that of H19 mutants; see Fig. 4e; Leighton et al.,
1995; Eggenschwiler et al., 1997). We propose then that the
particular GPC3 function that is related to overall somatic
growth operates only during embryonic development, i.e.,
the overgrowth of Gpc3/ or Gpc3/ mutants is exclusively
an embryonic phenomenon.
This view seems to conflict with the widely accepted
generalization that a predominant phenotypic feature of
SGBS is not only prenatal but also postnatal overgrowth.
We think, however, that, similarly to the mouse Gpc3
mutants, the overgrowth of SGBS patients also occurs only
during embryogenesis and that the expression “postnatal
overgrowth” is used loosely to simply describe “big body
size,” instead of referring to higher-than-normal growth
rate. Horizontal weight and height data for SGBS patients
are scarce and limited (for references, see legend to Fig. 4).
However, if they are used collectively, including values
recorded at single time points, and are superimposed on
smoothed percentile curves (ranging between the 50th and
97th percentiles) of postnatal weight and height growth
standards for males (http://www.cdc.gov/growthcharts), it
becomes immediately obvious that the patient growth data
follow normal trajectories (Figs. 4f and 4g). In fact, if the
allometric scaling equation y  a  xb is used in its
logarithmic form logy  loga  blogx, where y is body
length (BL), x is body weight (BW), b is the slope of the
regression line, and a is the y-intercept, it can be seen from
the results of regression analysis (not shown) that the
equation BL  30  BW0.4 (coefficient of correlation r 
0.99) fits almost exactly the growth standards and also the
data for SGBS patients (36 pairs of values from 25 patients).
Moreover, as Figs. 4f and 4g show, only very few of the
SGBS weight or height values exceed significantly the
TABLE 2
Additivity of GPC3 and IGF Actions on Body Weight
p0 p45
(A) Males
[II(0.85)  G(1.87)  W(1.54)]/GII(1.15)  1.03 [II(17.66)  G(32.20)  W(27.12)]/GII(21.2)  1.07
[I/(1.41)  G(1.87)  W(1.54)]/GI/(1.81)  0.96 [I/(25.00)  G(32.20)  W(27.12)]/GI/(30.10)  1.00
[R/(1.49)  G(1.87)  W(1.54)]/GR/(1.85)  0.98 [R/(24.41)  G(32.20)  W(27.12)]/GR/(28.11)  1.05
(B) Females
[II(0.85)  G/(1.70)  W(1.54)]/G/II(1.03)  0.98 [II(14.59)  G/(24.58)  W(22.41)]/G/II(17.00)  0.99
[G/(1.87)  W(1.54)]/G/(1.70)  W(1.54)]  2.06 [G/(26.68)  W(22.41)]/G/(24.58)  W(22.41)]  1.97
Note. With the exception of the last line, the ratios shown, which do not deviate significantly from unity, indicate that the GPC3 and
IGF actions on body weight are additive (if there is additivity, the weight of each double mutant should be equal to the weight of the single
mutant exhibiting growth deficiency increased by the weight excess of the single mutant exhibiting overgrowth; for details, see text). The
calculations shown in the last line indicate that the weight excess of Gpc3 female homozygous mutants is twice that exhibited by
heterozygotes. The weights at birth and at the age of 45 days used in the calculations are averages from the following numbers of mice of
each genotype shown in parentheses: W (wild-type; 46), G (Gpc3/; 38), II (Igf2/p; 23), GII (Gpc3//Igf2/p; 15 for p0; 5 for p45), I/ (Igf1/;
30), GI/(Gpc3//Igf1/; 14), R/(Igf1r/; 14), GR/(Gpc3//Igf1r/; 6), G/(Gpc3/; 55), G/(Gpc3/; 24), G/II (Gpc3//Igf2/p; 12).
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(normal) 97th percentile. However, such graph points
should have been the majority, if the postnatal growth rate
were higher than normal. This can be surmised from the
fact that 67% (18/27) of the known SGBS birth weights and
75% (9/12) of the known height values recorded at birth are
above the 97th percentile (Figs. 4f and 4g, insets). Never-
theless, it cannot be suggested from the available evidence
that there is transient growth retardation in patients as in
mutant mice (growth retardation associated with feeding
problems or illness has been described in very few SGBS
cases that are difficult to evaluate; see Opitz, 1984; Ko¨nig et
al., 1991).
The body size differences between Gpc3/ and normal
mice were reflected in the weights of various organs exam-
ined at embryonic and postnatal ages. Preliminary compara-
tive allometric regression analyses of organ and body
weights (log–log plots; data not shown) indicated that the
growth of the body and organs were mostly, but not always,
proportional in the Gpc3/ mutants. Thus, within the
limitations of these results, it can be concluded that the
heart, lungs, liver, kidney, stomach, and intestines followed
closely the changes in mutant body weight, whereas the
spleen-to-body allometric relationship was negative
(smaller spleen for the same weight, compared to wild type).
In contrast, the tongue and possibly the brain exhibited
positive allometric relationships in the mutants.
Importantly, the detailed analysis of somatic growth
(Figs. 4a, 4b, and 4e) allowed us to derive conclusive
evidence indicating that apparently there is no direct rela-
tionship between IGF signaling and the GPC3 role in
somatic growth. The hypothesis that the overgrowth of
Gpc3/ mutants is brought about by excess of IGF2 result-
ing from the absence of GPC3 that normally sequesters or
downregulates this ligand makes the strong prediction that,
in terms of somatic growth, double mutants lacking both
IGF2 and GPC3 would be phenotypically indistinguishable
from single Igf2/p mutants (proportionate dwarfs). Our
data show clearly that this is not the case, as the double
mutants are larger than the dwarfs lacking IGF2 (Fig. 4a).
Moreover, combination of Gpc3 heterozygosity with lack of
IGF2 in females (Gpc3//Igf2/p double mutants) again
resulted in mice larger than single Igf2/p female mutants
(Fig. 4b).
Without further analysis, these results cannot exclude
altogether an IGF2 involvement, but can be interpreted
minimally as indicating that, if GPC3 interacts with IGF2
at all, this ligand is not the only effector involved in the
growth-related function of GPC3. However, when the
weights of mutants and controls were compared quantita-
tively at birth (p0) and at p45 (i.e., at times when relative
growth retardation could not affect the calculations), it was
possible to show that the actions of IGF2 and GPC3 are just
additive and, therefore, most likely unrelated.
If W, G, II, and GII are, respectively, the average weights
of wild-type controls and Gpc3/, Igf2/p, and double
Gpc3//Igf2/p mutants at p0 or p45, the growth excess in
the absence of GPC3, as reflected in whole-body weight, is
a  G  W, whereas the growth deficit in the absence of
IGF2 is b  W  II (Table 2). If the actions of GPC3 and
IGF2 are independent, the weight GII of the double mutants
should be equal to the weight of the mutants lacking IGF2,
but increased by the excess a [II  (G  W)] or, from the
reciprocal point of view, it should be equal to the weight of
the mutants lacking GPC3, but decreased by the deficit b [G
(W  II)]. Therefore, the ratio (G  II  W)/GII should be
1.0. If, on the other hand, the weight excess a of Gpc3/
mutants is due to the absence of two GPC3 actions (a  a1
 a2), one of them independent (a1) and the other related to
IGF2 action (a2), the ratio (G  II  W)/GII should be 
1
because the a2 component of the excess would be missing
from the double mutants (same numerator, but smaller
denominator). As Table 2 shows, when the excess weight of
the Gpc3/ mutants is added to the weight of Igf2 mutants,
the sum matches almost exactly the weight of double
mutants, indicating that the actions of GPC3 and IGF2 on
somatic growth must be unrelated. This independence is
readily evident in the graph of Fig. 4e, where the values are
expressed as percentages of normal weight (%N). At p0 and
p45, the Gpc3/ and Igf2/p mutants are, respectively,
20% heavier and 40% lighter than normal (120%N
and 60%N), whereas the double mutants are 20%
lighter (80%N). Importantly, additional calculations dem-
onstrated that the described relationships also hold for
Gpc3/ and Gpc3//Igf2/p female mutants (Table 2).
Further supporting evidence was provided by analyzing
detailed growth curves (data not shown) of Igf1/ and
Igf1r/ heterozygotes, alone or in combination with the
Gpc3/ mutation and performing calculations, as described
above. Clearly, the known haploinsufficiency of Igf1/ and
Igf1r/ heterozygotes, as reflected in body weight (90–
92%N), was not maintained in double mutants also lacking
GPC3, but rather the effects of the mutations were additive
(see Table 2).
Consistent with the conclusion that there is no physical
interaction between GPC3 and IGF2, comparative measure-
ments of IGF2 concentrations in the serum and tissues of
Gpc3 null and wild-type embryos by Western analysis (Fig.
1d, and Table 3) demonstrated that there is no statistically
significant difference between the two groups, i.e., the
levels of IGF2 are normal, rather than elevated in the
TABLE 3
Relative Concentrations of IGF2
Wild type Gpc3/ a
Serum (e18.5) 100 	 14.0 (n  5) 93.2 	 16.3 (n  5) –
Embryonic extract
(e18.5)
100 	 11.2 (n  5) 83.6 	 8.2 (n  5) –
Amniotic fluid
(e16.5)
100 	 9.4 (n  3) 94.8 	 19.9 (n  3) –
a There is no statistically significant difference () between the
samples from wild-type controls and mutants lacking GPC3.
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mutants, in agreement with analogous previous measure-
ments (Cano-Gauci et al., 1999). Additional assays were
performed to assess IGF2 levels in amniotic fluid that
reportedly contains in humans soluble GPC3 capable of
binding IGF2 with high affinity (Xu et al., 1998). Again, a
difference between mutants and controls was not detected
(Table 3).
Interestingly, as already noted for embryos, the absence of
GPC3 in double Gpc3//H19 mutants did not augment the
somatic overgrowth resulting from excess of IGF2. Thus,
the birth weight of offspring with a Gpc3//H19 genotype
was 2.09 	 0.05 g on average (n  21), whereas in single
H19 and Gpc3/ mutants, it was 2.02	 0.09 g (n 19) and
1.90 	 0.04 g (n  38), respectively. At p45, the weights of
single male H19 and Gpc3/ mutants were the same
(32.7 	 0.89 and 32.2 	 0.55 g, respectively). Male double
mutants did not survive to this age to be analyzed, but the
average weight of three female Gpc3//H19 survivors was
24.87 	 0.09 g, i.e., slightly lower than that of Gpc3/
females (26.68 	 0.54 g, n  24; H19 females were not
available for comparison, as they were not obtained from
the G/H cross).
CONCLUDING REMARKS
The whole-body overgrowth of Gpc3/ mutants that is
manifested with concomitant organ-specific differences in
allometric relationships to body size, including both posi-
tive and negative effects, in conjunction with the detected
tissue-specific (regional) histopathological changes reflect-
ing morphogenetic lesions, suggest that GPC3 interacts
with various effectors. Unraveling the identity and roles of
these effectors will probably turn out to be a slow and
difficult process because, in future experiments, the nature
of the abnormalities in growth and morphogenesis that the
absence of GPC3 provokes would continue to require the
use of the entire mammalian organism as an assay system
providing a proper context. Still, at least some guiding clues
may be gained from in vitro assays, experiments with
cultured cells, or paradigms from other model organisms,
such as the interactions of a Drosophila glypican (the dally
gene product) with components of the Wg/Wnt and other
signaling pathways (Tsuda et al., 1999; Lin and Perrimon,
1999, 2000). However, despite a likely participation of some
FGF or TGF family members, which potentially interact
with GPC3, in regional patterning events (see De Cat and
David, 2001), there is no known and immediately recogniz-
able candidate that can be proposed as being involved in
general (whole-body) overgrowth. A few comments focus-
ing exclusively on this aspect of the Gpc3/ phenotype are
presented below.
Because the increased growth of Gpc3/ mutants corre-
sponds to hyperplasia and not to hypertrophy, a key mecha-
nistic question is whether the overgrowth observed in the
absence of GPC3 is brought about by an increase in prolif-
eration or a decrease in apoptosis. The limited information
that is currently available (Gonzalez et al., 1998) suggests
that GPC3 apparently promotes apoptosis by reducing an-
tiapoptotic signaling, which should be increased in its
absence. However, the effect appears to be cell-specific (at
least by the criterion of the cell lines used in the experi-
ments) and, therefore, inconsistent with a general somatic
role. Moreover, against expectation from these results, a
significant increase in apoptosis was observed in the kid-
neys of Gpc3/ mutants (Grisaru et al., 2001).
Considering the situation further, we think that it is
quite unlikely that antiapoptotic function could be in-
volved in Gpc3/ somatic overgrowth. Apoptotic functions
are effected by a complex multicomponent network that
presumably includes participants with overlapping roles.
Most probably, therefore, opportunistic compensation of
function would be provided upon gene targeting of any
single member. In fact, although knockout of the antiapop-
totic Bcl2 gene resulted in severe postnatal growth retarda-
tion (Veis et al., 1993), generalized overgrowth was not
observed by knocking-out genes encoding proapoptotic ef-
fectors. For example, elimination of either caspase 3 (Kuida
et al., 1996; Woo et al., 1998) or caspase 9 (Kuida et al.,
1998; Hakem et al., 1998) resulted only in neuronal hyper-
plasia. Although some of the regional phenotypic charac-
teristics of Gpc3/ mutants may be related to apoptosis, we
found no evidence that such effects could be predominant,
at least in mice. A characteristic example of the develop-
mental role of apoptotic pathways is the sculpting of limbs
during embryogenesis. However, interdigital webbing occa-
sionally observed in SGBS patients (Neri et al., 1988;
Hughes-Benzie et al., 1992a) was absent from Gpc3/ mu-
tants against expectation, although it would have been
detectable, had it occurred. Persistence of interdigital tissue
that normally undergoes apoptosis and disappears by e15.5
is, for example, a feature of hammertoe mouse mutants (see
Ahuja et al., 1997) and of surviving Bax/Bak/ double
nullizygotes (the corresponding genes encode proapoptotic
proteins; Lindsten et al., 2000).
The mechanism by which GPC3 participates in overall
somatic growth regulation remains elusive. We favor, how-
ever, the view that, to play this particular role, the
membrane-bound GPC3 interacts with a systemically act-
ing and, therefore, diffusible factor, rather than with com-
ponents of the extracellular matrix. For simplicity, we will
assume that this presumptive factor (G3IF, for “glypican
3-interacting factor”) is unique. For an involvement in
proliferation and, therefore, organismal growth, the signal-
ing that G3IF elicits after binding to its cognate receptor
should affect the cell cycle. In principle, however, the mode
of action can be either positive or negative. GPC3 could be,
for example, a coreceptor augmenting the binding of
growth-inhibitory G3IF to its receptor. Inefficient binding
in Gpc3/ mutants would result in reduction of negative
signaling, overactivity of growth promoters that are no
longer counterbalanced, and overgrowth. An alternative
hypothesis, which we prefer because it is more parsimoni-
ous, is that G3IF could be a growth-promoting factor that is
201Genetic Analysis of Glypican-3 Null Mice
© 2002 Elsevier Science (USA). All rights reserved.
sequestered and becomes ineffective upon binding to GPC3.
In this scenario, which is identical to the one originally
proposed for IGF2, overgrowth would result from excess of
G3IF in Gpc3/ mutants.
Although, as we have shown here, IGF2 and G3IF are
different factors serving independent signaling pathways,
we propose a model postulating that there is convergence of
their signal transduction relays to common downstream
effectors. This view can account for the similarity in Igf2
and Gpc3 expression patterns (DeChiara et al., 1991; Pelle-
grini et al., 1998) and for the growth saturation phenom-
enon that we described in Gpc3//H19 double mutant
embryos, which is accompanied by additive (nonconverg-
ing) effects on placental growth of excess IGF2 and postu-
lated excess of G3IF. Moreover, consistent with the model
are additional phenotypic manifestations in the same mu-
tants, for example, omphalocele and vertebral anomalies.
We have previously described such features in double
mutants carrying the H19 mutation and also lacking the
type 2 IGF receptor (IGF2R) because of knockout of the
normally active maternal allele of the imprinted cognate
gene. These mutants (Igf2rm//H19) express IGF2 at very
high levels because of elimination of IGF2R-mediated IGF2
turnover in combination with biallelic Igf2 transcription
(Eggenschwiler et al., 1997). In contrast, the single H19
mutants do not manifest omphalocele or skeletal anomalies
(Leighton et al., 1995; Eggenschwiler et al., 1997). There-
fore, the partial phenotypic overlap between the Igf2rm//
H19 and Gpc3//H19 double mutants, which share the
H19 mutation, is highly suggestive of the existence of
common downstream effectors for IGF2 and G3IF, since the
presumptive excess of G3IF signaling in Gpc3//H19
double mutants or the extra amount of IGF2 (provided by
the Igf2rm/ mutation) in Igf2rm//H19 double mutants
appear to have similar consequences. Interestingly, how-
ever, G3IF does not simulate IGF2 action in all tissues. For
example, the single Igf2rm/ and double Igf2rm//H19
mutants exhibit cardiac abnormalities (heart enlargement
with persistence of early embryonic sinusoids resulting in
heart failure) that are absent from Gpc3//H19 double
mutants.
Although SGBS and BWS (see Introduction) are clinically
distinct conditions, they exhibit overlapping phenotypic
features, including overgrowth, to such a degree that mis-
diagnosed cases are not uncommon (Hughes-Benzie et al.,
1992b; Verloes et al., 1995). Keeping in mind that at least
some of the BWS cases can be attributed to IGF2 excess
(see Li et al., 1998; Maher and Reik, 2000) and that the
Igf2rm//H19 double mutants manifest features of both
BWS and SGBS (Eggenschwiler et al., 1997), we think that
our model of independent but converging IGF2 and G3IF
signaling can account for the common and distinct pheno-
typic elements of these two syndromes. Overstimulation by
either factor would result in somatic overgrowth associated
with common or different, tissue-specific dysmorphoge-
netic consequences. It may turn out that the principle of
convergence could be extended to explain clinical overlaps
between the BWS or SGBS and Perlman syndrome (see
Verloes et al., 1995; Coppin et al., 1997; Li et al., 2000) or
additional overgrowth conditions.
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